Robert Califf was approved in a 50-46 vote by the senate
Dr. Robert Califf, a cardiologist, was confirmed on Tuesday to head the U.S. Food and Drug Administration in a 50-46 senate vote.
Califf previously was confirmed to run the agency during President Obama’s last year in office by an 89-4 vote. He previously served as the FDA’s deputy commissioner for medical products and tobacco. Prior to his FDA assignments, he was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He was also director of the Duke Translational Medicine Institute and is the founding director of the Duke Clinical Research Institute.
Six Republicans voted for him and five Democrats voted against him, most notably Sen. Joe Manchin of West Virginia who expressed concerns about Califf’s ties to the pharmaceutical industry. Manchin wants the FDA to be more focused on stopping the opioid epidemic and does not believe Califf is the right person to change the culture at the FDA to do so.
Sen. Elizabeth Warren, a Massachusetts Democrat voted yes after meeting with Califf and asking him to sign an ethics pledge that mandates that he won’t work for any company he oversees at the FDA for at least four years after he finishes. Califf signed the pledge.
He also faced opposition from a coalition of pro-life groups, including the Susan B. Anthony List, after he said during his confirmation hearing that he trusted the FDA’s process about the agency’s decision to allow abortion pills to be sent by mail.
This article was originally published by sister publication Medical Economics.
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.